A practical reference on reconstitution: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-02-24. Anything still debated is marked as such rather than presented as settled.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H68N10O14 | Calculated for the acetylated heptapeptide |
| Molecular weight | ~889 Da | Monoisotopic mass approximately 889.0 Da |
| Amino acid sequence | Ac-LKKTETQ | N-terminal acetylated seven-residue peptide |
| Appearance | White to off-white powder | Typically supplied as a lyophilized solid |
| Solubility class | Water-soluble | Peptides of this size generally dissolve in aqueous media |
Identity and purity are assessed with a small set of standard techniques. Reverse-phase high-performance liquid chromatography gives a purity estimate from peak area, usually recorded at 214 or 220 nanometers, where the peptide bond absorbs. Mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidized species. Amino acid analysis or tandem mass spectrometry sequencing can verify the sequence itself. Additional quality attributes include water content, residual trifluoroacetic acid carried over from purification, and endotoxin where the material is intended for biological work.
The compound is most often distributed as a lyophilized powder, appearing white to off-white and forming a loose cake or fluffy solid. It is hygroscopic to some degree, so brief exposure to humid air can add water weight and complicate weighing. The peptide dissolves readily in water and in neutral aqueous buffers, and aqueous solubility is generally described as high, well above the concentrations used in typical assays. Some polar organic solvents are also usable, which matters when a concentrated stock is prepared before dilution into buffer.
Storage recommendations center on keeping the dry powder cold, dry, and dark. A freezer at -20 degrees Celsius or below is conventional, and desiccant is often included to limit moisture uptake. Once dissolved, the peptide is less stable, and solutions are typically kept frozen and thawed only once. Repeated freeze-thaw cycles are a common source of losses because they promote aggregation and adsorption to container surfaces. Working aliquots are therefore prepared in advance, and glass or low-binding plastic is usually preferred over ordinary laboratory plastic.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.
Identity and purity checks for peptide material typically combine reversed-phase high-performance liquid chromatography with mass measurement, since retention time alone cannot confirm a sequence. Mass measurement verifies the expected molecular mass within instrument tolerance, while chromatographic peak area provides a purity estimate. Anti-doping analysis of urine uses related but more sensitive workflows, sometimes after solid-phase extraction. For research material, batch documentation, certificate content, and independent testing are common points of scrutiny, because supply chains outside pharmaceutical regulation vary widely in the paperwork they provide.
Reconstitution of a lyophilized peptide is normally done with sterile water or a suitable buffer under aseptic conditions. Adding solvent down the vial wall and allowing gentle dissolution instead of vigorous vortexing reduces the chance of aggregation, which can lower the effective concentration of the resulting solution. Concentrated stocks are usually diluted into working buffer shortly before use. Because no standard preparation protocol exists for TB-500 specifically, laboratories adapt general peptide handling practice, and reported results may reflect differing preparation choices.
Research peptides are typically supplied as a white to off-white lyophilised powder in a sealed vial. The dry solid is more stable than a solution and is normally kept refrigerated or frozen until use. Dissolution is usually done in water, phosphate-buffered saline or a similar aqueous medium, depending on the assay. Because the material is hygroscopic and easily contaminated, opening vials in a low-humidity environment and recording the lot number before use are standard laboratory practices.
Once in solution, short peptides are generally less stable than the dry powder, and repeated freeze-thaw cycles are a common cause of loss. Laboratory guidance usually calls for aliquoting on first dissolution and storing aliquots at -20 °C or below, away from light. Adsorption to plastic and glass surfaces can lower measured concentration, particularly at low concentrations, so container material and buffer choice can affect results. Visible cloudiness, colour change or unexpected precipitate is a signal to re-check the material.
==== Evolutionary covariation to predict 3D contacts ==== As sequencing became more commonplace in the 1990s several groups used protein sequence alignments to predict correlated mutations and it was hoped that these coevolved residues could be used to predict tertiary structure (using the analogy to distance constraints from experimental procedures such as NMR). The assumption is when single residue mutations are slightly deleterious, compensatory mutations may occur to restabilize residue-residue interactions. This early work used what are known as local methods to calculate correlated mutations from protein sequences, but suffered from indirect false correlations which result from treating each pair of residues as independent of all other pairs. In 2011, a different, and this time global statistical approach, demonstrated that predicted coevolved residues were sufficient to predict the 3D fold of a protein, providing there are enough sequences available (>1,000 homologous sequences are needed). The method, EVfold, uses no homology modeling, threading or 3D structure fragments and can be run on a standard personal computer even for proteins with hundreds of residues. The accuracy of the contacts predicted using this and related approaches has now been demonstrated on many known structures and contact maps, including the prediction of experimentally unsolved transmembrane proteins.
{\displaystyle {\begin{aligned}\Delta p={\frac {1}{2}}\rho {\overline {v}}_{\text{max}}^{2}&={\frac {1}{2}}\rho \left({\frac {Q_{\text{max}}}{\pi R^{2}}}\right)^{2}\\\Rightarrow \quad Q_{\max }{}&=\pi R^{2}{\sqrt {\frac {2\Delta p}{\rho }}},\end{aligned}}}
Watson had a good start to the 2014 season, but he injured his hip flexor in round 12 and consequently missed ten weeks. Watson later returned to play in the final three games of the home-and-away season and Essendon's elimination final loss to North Melbourne. Watson then went on to poll eight Brownlow votes, behind up-and-coming midfielder and future captain Dyson Heppell. Watson was also selected in the Australian team for the first time in his career to play in the 2014 International Rules Series. Watson was among the best players in the one-test series, which Australia won by ten points. In 2015, despite controversy surrounding the team's lack of fitness (following a compromised pre-season) and a tough first half of the season for Essendon, Watson continued to lead his team well early in the season despite his own injury clouds. In Round 14, Watson played his 200th AFL game in what proved to be a torrid day for the Bombers, as they lost to St Kilda by 110 points. Following that match, Watson was ruled out for the rest of the season with a shoulder injury, having injured it the previous week; Watson polled seven Brownlow votes in the first five rounds prior to the injury. He was later banned for the 2016 season as part of the club's supplements saga. Watson played his first competitive match in over eighteen months – and his first without being captain of the club since 2009 – when he and several of the other Essendon players who served bans in 2016 made their return to the field against Collingwood in the 2017 pre-season.
==== Promethazine ==== Promethazine is one of the recommended drugs by NASA to treat space motion sickness and studies have been conducted to analyze their pharmacological responses in outer space. Studies on promethazine were performed exclusively on Earth, called earthbound models, stimulating microgravity and weightlessness through forty-eight hours of bed rest. The −6° head-down best rest model, where individuals are placed lying 6 degrees down to study weightlessness. This type of model simulates the shift in fluid from the bottom to the top of the body, as well as bone loss, found in astronauts in weightless environments. Using twelve volunteers, 50 mg of promethazine was delivered orally or intramuscularly to the deltoid muscle before and after forty-eight hours of bedrest. Blood was examined at intervals of 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-drug deliverance and promethazine levels were detected using plasma promethazine assays, which uses liquid chromatography to quantify promethazine kinetics. The study determined that higher concentrations of promethazine were found in the blood through oral delivery and bioavailability factors was impacted through weightlessness.
The triple quadrupole mass spectrometer essentially operates under the same principle as the single quadrupole mass analyzer. Each of the two mass filters (Q1 and Q3) contains four parallel, cylindrical metal rods. Both Q1 and Q3 are controlled by direct current (dc) and radio-frequency (rf) potentials, while the collision cell, q, is only subjected to RF potential. The RF potential associated with the collision cell (q) allows all ions that were selected for to pass through it. In some instruments, the normal quadrupole collision cell has been replaced by hexapole or octopole collision cells which improve efficiency. Unlike traditional MS techniques, MS/MS techniques allow for mass analysis to occur in a sequential manner in different regions of the instruments. The TQMS follows the tandem-in-space arrangement, due to ionization, primary mass selection, collision induced dissociation (CID), mass analysis of fragments produced during CID, and detection occurring in separate segments of the instrument. Sector instruments tend to surpass the TQMS in mass resolution and mass range. However, the triple quadrupole has the advantage of being cheaper, easy to operate and highly efficient. Also, when operated in the selected reaction monitoring mode, the TQMS has superior detection sensitivity as well as quantification. The triple quadrupole allows the study of low-energy low-molecule reactions, which is useful when small molecules are being analyzed.
Sources: en.wikipedia.org
On January 3, 2020, Cold Stone Creamery announced that it would close its doors on January 31, 2020, in Singapore. In March 2015, Cold Stone opened its first location in Turkey's capital Ankara. In 2015 Cold Stone Creamery opened its first location in El Salvador in Multiplaza Mall and in April 2023, Cold Stone opened its first United Kingdom location in Charing Cross Road. In May 2007, Cold Stone Creamery merged with Kahala Corp to form Kahala-Cold Stone, which collectively owns 8 brands. Doug Ducey, who had served as president and CEO of Cold Stone Creamery since 1995, and future Governor of Arizona, was named CEO of the new company. Kevin Blackwell, the former CEO of Kahala, became chairman of the board and chief strategist. However, in September 2007, Ducey announced he was leaving the company. Blackwell was named CEO. In 2013, the Serruya family, based in Toronto, Ontario, purchased a majority interest in Kahala and changed the name to Kahala Brands to better align with the focus of the business. After a decade of operation, Cold Stone Creamery closed all its outlets in Singapore on January 31, 2020.
It resembles Grisons Buendnerfleisch, and first appears in works on gastronomy from about 1560. Bündnerfleisch – an air-dried meat that is produced in the canton of Graubünden, Switzerland, The main ingredient is beef, taken from the animal's upper thigh or shoulder, the fat and the sinews being removed. Before drying, the meat is treated with white wine and seasonings such as salt, onion and assorted herbs.
Border security refers to measures taken by one or more governments to enforce their border control policies. Such measures target a variety of issues, ranging from customs violations and trade in unlawful goods to the suppression of unauthorized migration or travel. The specific border security measures taken by a jurisdiction vary with local authorities' priorities and are influenced by social, economic, and geographical factors. Some countries use deadly force to deter illegal entry. Sanctions for attempted illegal entry were found to deter repeated attempts (recidivism). In India, which maintains free movement with Nepal and Bhutan, border security focuses primarily on the Bangladeshi, Pakistani, and Myanmar borders. India's primary focus with regard to the border with Bangladesh is to deter unlawful immigration and drug trafficking. On the Pakistani border, the Border Security Force aims to prevent the infiltration of Indian territory by terrorists from Pakistan and other countries in the west (Afghanistan, Iraq, Syria, etc.). In contrast, India's border with Myanmar is porous and the 2021 military coup in Myanmar saw an influx of refugees seeking asylum in border states including Mizoram. The refoulement of Rohingya refugees is a contentious aspect of India's border control policy vis à vis Myanmar. Meanwhile, American border security policy is largely centred on the country's border with Mexico. Security along this border comprises many distinct elements, including physical barriers, patrol routes, lighting, and border patrol personnel.
Vaccine hesitancy is a delay in acceptance, or refusal of vaccines despite the availability of vaccine services. The term covers outright refusals to vaccinate, delaying vaccines, accepting vaccines but remaining uncertain about their use, or using certain vaccines but not others. There is an overwhelming scientific consensus that vaccines are generally safe and effective. Vaccine hesitancy often results in disease outbreaks and deaths from vaccine-preventable diseases. The World Health Organization therefore characterized vaccine hesitancy as one of the top ten global health threats in 2019.
==== Usage of Protein Nanoprobes to Study Protein-Protein Interactions with Mass Spectrometry ==== Protein was studied using a protein nanoprobe (that enables cross-linking) that introduced photo-methionine within the protein (during the recombinant expression) which lead to the protein keeping its reserved structure while having the ability to be mapped out for its interactions. The model was used as a region of contact surface that is involved in a well-known interaction (homodimerization) between two molecules of 14-3-3ζ protein. Once the photo-methionine is introduced and has become activated using UV-light, it can cross-link with no specificity (meaning no group) and the links have zero-length. High resolution mass spectrometry or MS can (even MS/MS) be used then to determine the cross-linked residues and the reaction radius; allowing the researchers to characterize and research the homodimerization of the protein. The usage of the high-resolution MS with photo-methionine has its advantages as it again allows the protein to be in its native state, there are reasonable time scales while using small quantities of the protein. There are also fewer limitations on the reaction specificity and restrictions using a photo-active cross-linker (photo-methionine) compared to chemical cross-linking. This method of combined photo-initiated cross-linking from the protein nanoprobe in tandem with MS could be useful to characterize not only homodimer formation but also oligomers and in theory; heteromers (such as the composition of the protein-protein mixture and its functionality).
Sources: en.wikipedia.org
TB-500 is a synthetic heptapeptide corresponding to a fragment of thymosin beta-4. It is used in laboratory research and is not an approved drug.
No. Thymosin beta-4 is a 43-amino-acid protein, while TB-500 represents only a short N-terminal segment. The two should not be treated as interchangeable in experimental design.
It is often called a thymosin beta-4 fragment, Tβ4 fragment, or Ac-LKKTETQ. The name TB-500 is mainly a commercial or catalog label rather than a formal chemical name.
Most listings describe it as a short acetylated peptide with the sequence Ac-LKKTETQ, presented as a region of thymosin beta-4. The label is a trade-style name rather than a standardized chemical name, so the exact content of a given vial depends on the supplier.